Craig-Hallum Maintains Buy on Cardlytics, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Jason Kreyer maintains a Buy rating on Cardlytics (CDLX) but lowers the price target from $18 to $12.

May 09, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Craig-Hallum maintains a Buy rating on Cardlytics but lowers the price target from $18 to $12.
While the maintenance of a Buy rating suggests continued confidence in the company's fundamentals, the reduction in the price target could indicate concerns about near-term growth prospects or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the implications.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100